The Crowley Center for Regenerative Biotherapeutics and SESDERMA S.L. have entered into a global, exclusive, and renewable 10-year Strategic Alliance aimed at advancing regenerative medicine, longevity, and anti-aging therapies.
The Crowley Center for Regenerative Biotherapeutics and SESDERMA S.L. have entered into a global, exclusive, and renewable 10-year Strategic Alliance aimed at advancing regenerative medicine, longevity, and anti-aging therapies. The partnership combines the Crowley Center’s expertise in regenerative biologics, stem cell–derived exosomes, and longevity platforms with SESDERMA’s leadership in nanotechnology, dermocosmetic formulation, and global commercialization.
The Alliance focuses on the co-development of innovative regenerative products leveraging proprietary nanotechnology systems to enhance bioavailability, tissue penetration, efficacy, and safety. Key areas include nano-encapsulation of MSC-derived umbilical cord exosomes, co-formulation with SESDERMA’s regenerative dermocosmetic actives, technology cross-licensing, and contract manufacturing.
The collaboration also integrates artificial intelligence for diagnostics and personalized treatments, as well as advanced longevity technologies such as Transcranial Photobiomodulation Therapy. As part of its long-term vision, the Alliance plans to establish a global network of Regenerative Longevity Centers across major international markets. This agreement establishes a platform for regenerative aesthetics and reverse-aging applications, with future expansion into broader medical and therapeutic indications.
